Nanoparticle albumin-bound paclitaxel for breast cancer
Record ID 32013000818
English
Authors' recommendations:
Nanoparticle albumin-bound paclitaxel (nab-paclitaxel) (Abraxane; Abraxis BioScience LLC, a wholly owned subsidiary of Celgene Corp.) is a chemotherapeutic drug that is administered alone or in combination with other agents for the purpose of delaying disease progression and prolonging survival in patients who have metastatic breast cancer. Nab-paclitaxel differs from standard paclitaxel in that it is a colloidal suspension of 130-nanometer albumin-bound nanoparticles of paclitaxel and is, therefore, free of solvents. The goals of this new nanotechnology-based formulation are to reduce toxicity and improve the bioavailability of paclitaxel.
Details
Project Status:
Completed
Year Published:
2013
URL for published report:
The report may be purchased from: http://www.hayesinc.com/hayes/crd/?crd=10887
English language abstract:
An English language summary is available
Publication Type:
Not Assigned
Country:
United States
MeSH Terms
- Antineoplastic Agents
- Albumins
- Paclitaxel
Contact
Organisation Name:
HAYES, Inc.
Contact Address:
157 S. Broad Street, Suite 200, Lansdale, PA 19446, USA. Tel: 215 855 0615; Fax: 215 855 5218
Contact Name:
saleinfo@hayesinc.com
Contact Email:
saleinfo@hayesinc.com
Copyright:
2013 Winifred S. Hayes, Inc
This is a bibliographic record of a published health technology assessment from a member of INAHTA or other HTA producer. No evaluation of the quality of this assessment has been made for the HTA database.